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Abstract 
Background: Allogeneic hematopoietic cell transplantation (allo-HCT) has been proposed as 
treatment for multiple sclerosis (MS) and other autoimmune diseases.  
Aims: To describe the effects of allo-HCT on the course of MS in a 49-year-old woman with 
longstanding progressive MS who was treated with allo-HCT for follicular lymphoma.  
Methods: Non-myeloablative conditioning allo-HCT, examination for IgG oligoclonal bands 
and measurement of CXCL13 and matrix metalloproteinase-9 (MMP-9) concentration in the 
cerebrospinal fluid (CSF).  
Results: Despite the disappearance of oligoclonal bands in CSF, disease progression and CSF 
inflammation was observed.  
Conclusions: We hypothesize that CXCL13 and MMP-9 detected in CSF may reflect ongoing, 
pathogenic immune activation even after the eradication of intrathecal IgG synthesis. This 
suggests that progressive MS may depend more on innate than on adaptive immune 
activation.  
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Introduction 
Autologous hematopoietic cell transplantation (auto-HCT) treatment for multiple 
sclerosis (MS) involves high-dose chemotherapy (immunosuppression) that 
requires ‘rescue’ of the hematopoietic system with blood stem cells [1, 2]. In allogeneic 
hematopoietic cell transplantation (allo-HCT) the graft is obtained from an 
HLA-matched donor. In allo-HCT with myeloablative conditioning high-dose 
chemo-radiotherapy is given with the aim of eradicating the last tumor cell. Allo-HCT 
with non-myeloablative conditioning exploits the fact that the curative effect is mainly 
achieved by the ability of the donor immune system to eradicate recipient 
hematopoietic cells including malignant cells. The conditioning is mild and given only 
to prevent rejection of the donor cells [3]. 
Case Presentation 
In July 2006 we treated a 49-year-old woman with MS with non-myeloablative conditioning 
allo-HCT for follicular lymphoma grade 1–2, stage IV. Prior to the transplant the lymphoma was 
brought into complete remission with chemotherapy. The graft consisted of peripheral blood stem 
cells from an HLA-identical sister (table 1). 
Relapsing-remitting MS with onset in 1985 evolved into secondary progressive MS from 2000. She 
did not want immunomodulatory treatment at any time. She had no MS relapses from 2004 to 2006. 
Prior to HCT her expanded disability status scale (EDSS) score was 3.5 and her MS impairment scale 
(MSIS) score was 31 [4]. Following HCT she had new MRI disease activity and showed EDSS 
progression due to impairment of walking ability, which according to the patient partially resulted 
from pain after a deep venous thrombosis of the leg (table 1). Her MSIS score, which quantitates 
abnormalities on a standard neurological examination, also increased after HCT, but improved at later 
follow-up visits. 
Before HCT she had IgG oligoclonal bands in cerebrospinal fluid (CSF) (fig. 1). B cell chemokine 
CXCL13 and matrix metalloproteinase-9 (MMP-9) levels in CSF, measured with commercially 
available ELISA kits (R&D Systems, Abingdon, UK), were normal. 
One-year post-transplant CSF examination was negative for oligoclonal bands, and MMP-9 levels 
were normal, but CXCL13 was detectable (fig. 1 and table 1). In April 2010 IgG oligoclonal bands 
remained absent, but CXCL13 was still detectable and the MMP-9 concentration had increased 
(table 1). CXCL13 concentrations were not measured in serum or plasma samples. Therefore, it 
cannot be excluded that CXCL13 in CSF might arise from plasma. Previous studies of CXCL 13 have, 
however, not detected CXCL13 in plasma in sufficiently high concentrations to have an impact on the 
CXCL13 concentrations measured in CSF [5]. We therefore consider it most likely that the CXCL13 
measured in CSF arises from local synthesis. Furthermore, a polyclonal intrathecal IgG synthesis 
occurring in the absence of oligoclonal IgG synthesis is a theoretical possibility, but would be highly 
unusual in the setting of MS [6]. 
Discussion 
The relationship between inflammation, demyelination and axonal pathology 
in MS is not resolved. Inflammation in relapsing-remitting MS is associated with 
demyelination and axonal loss. In progressive MS this relationship is less clear and it is 
thought that axonal degeneration may continue in the absence of overt inflammation 
[7], however, recent studies challenge this notion [8].  
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A handful of cases of MS patients treated with allo-HCT for malignant hematological 
disease have been published [1]. In two recent reports continued disease activity 
was observed after transplantation [9, 10]. In our patient allo-HCT was associated 
with the disappearance of IgG oligoclonal bands. This has also been observed in 
auto-HCT-treated MS patients [2]. However, serial CSF studies showed that even 
though IgG oligoclonal bands disappeared, CXCL13 and MMP-9 concentrations were 
increased. CXCL13 is expressed in perivascular infiltrates and within the brain 
parenchyma in MS, and CSF concentrations of CXCL13 are increased in secondary 
progressive MS [5, 11]. Secondary progressive MS patients with a more severe disease 
course harbor lymphoid follicle-like structures in the meninges, and CXCL13 may be 
involved in the generation of these structures [12]. MMP-9 in CSF has also been 
associated with disease activity in MS [13]. In an autopsy study it was observed that 
although lymphocytes and plasma cells were almost absent after auto-HCT, there was 
ongoing microglia activation, demyelination, and axonal pathology [14]. We 
hypothesize that CXCL13 and MMP-9 detected in the CSF of our patient may reflect 
ongoing, pathogenic, immune activation associated with continuing tissue damage even 
after the eradication of intrathecal IgG synthesis. This is consistent with the notion that 
progressive MS may depend more on innate than on adaptive immune activation [8, 
15]. 
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Table 1. Overview of events, treatment, scores, paraclinical, and clinical findings 
                 
                  Date  Clinical events  Treatment  EDSS 
score 
MSIS 
score 
MRI  Oligoclonal  
bands 
CXCL13  MMP-9 
                                   
1985  MS               
Nov. 2003  follicular lymphoma  CVP, FC             
June 2006  CR of lymphoma    3.5  31  >10 T2 brain lesions, 
spinal MRI not done 
positive  undetect-
able 
undetectable 
July 2006  Allo-HCT  FA, TBI, CsA, MMF1             
Aug. 2006    CsA, MMF  3.5  30         
Jan. 2007  acute GVHD  MEP, CsA, MMF, Infliximab             
April 2007   CsA, MMF, PSL  4  39         
Sept. 2007    MEP/PSL, MMF, TAC      several new brain lesions  
and 2 spinal cord lesions 
     
Dec. 2007  acute GVHD resolved/ 
full donor chimera 
MMF, TAC, PSL             
July 2008  chronic GVHD  PSL, TAC, MMF             
Aug. 2008    PSL, TAC, MMF      1 new brain lesion; 
1 spinal cord lesion 
resolved 
negative  27 pg/ml  undetectable 
Sept. 2008  CR of lymphoma  PSL, TAC, MMF             
Dec. 2008    PSL, TAC, MMF  5  33         
April 2010   TAC        negative  24 pg/ml  1.71 ng/ml 
June 2010    TAC      no changes       
May 2011    TAC  5.5  32         
                                    1 The patient has been receiving immunoglobulin replacement therapy since July 2006 due to hypogammaglobulinemia.  
MRI = Magnetic resonance imaging; CXCL13 = C-X-C motif chemokine 13 (undetectable, i.e., <7.8 pg/ml in control subjects); MMP-9 = matrix 
metalloproteinase-9 (undetectable, i.e., <0.0312 ng/ml in control subjects); GVHD = graft-versus-host disease; CR = complete remission; 
CVP = cyclophosphamide, vincristine, prednisolone; FC = fludarabine, cyclophosphamide; FA = fludarabine; TBI = total body irradiation; 
MEP = methylprednisolone; CsA = cyclosporine A; PSL = prednisolone; MMF = mycophenolate mofetil; TAC = tacrolimus.  
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Fig. 1. Results of isoelectric focusing of IgG in CSF and serum from 2006 (before transplantation) and 
after transplantation in 2008 and 2010. The anode of the gel is at the bottom of the gel and the 
cathode is at the top of the gel. Oligoclonal bands are depicted by arrowheads. IgG oligoclonal bands 
were studied by isoelectric focusing in a commercially available isoelectric focusing gel followed by 
immunofixation with anti-IgG antibody and protein staining of fixed IgG-anti-IgG complexes in the 
gel (Hydragel 9 CSF isofocusing, Sebia Electrophoresis, Norcross, USA). 
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